ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 86 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2021. The put-call ratio across all filers is 1.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,374,980 | -15.8% | 17,147,409 | -0.2% | 0.01% | -14.3% |
Q2 2023 | $15,887,926 | -14.8% | 17,176,135 | +0.4% | 0.01% | -17.6% |
Q1 2023 | $18,652,082 | -25.6% | 17,112,002 | -0.3% | 0.02% | -34.6% |
Q4 2022 | $25,068,111 | +59.0% | 17,169,939 | +17.1% | 0.03% | +62.5% |
Q3 2022 | $15,764,000 | -39.5% | 14,664,936 | -4.3% | 0.02% | -40.7% |
Q2 2022 | $26,046,000 | -17.8% | 15,321,346 | -0.4% | 0.03% | +22.7% |
Q1 2022 | $31,684,000 | -38.6% | 15,380,538 | +11.8% | 0.02% | -21.4% |
Q4 2021 | $51,587,000 | -22.2% | 13,756,352 | +7.3% | 0.03% | -20.0% |
Q3 2021 | $66,306,000 | +33.1% | 12,824,980 | +9.6% | 0.04% | +45.8% |
Q2 2021 | $49,828,000 | -18.2% | 11,696,919 | +2.0% | 0.02% | -29.4% |
Q1 2021 | $60,892,000 | +9.1% | 11,467,517 | +10.7% | 0.03% | +9.7% |
Q4 2020 | $55,828,000 | -1.2% | 10,357,780 | +46.3% | 0.03% | -20.5% |
Q3 2020 | $56,482,000 | +6.7% | 7,078,063 | +33.8% | 0.04% | -2.5% |
Q2 2020 | $52,950,000 | +347.1% | 5,289,669 | +21.5% | 0.04% | +207.7% |
Q1 2020 | $11,843,000 | +130.2% | 4,354,023 | +1.6% | 0.01% | +160.0% |
Q4 2019 | $5,145,000 | -18.2% | 4,287,545 | +2.9% | 0.01% | -28.6% |
Q3 2019 | $6,289,000 | -62.2% | 4,164,807 | +0.5% | 0.01% | -61.1% |
Q2 2019 | $16,658,000 | +0.9% | 4,143,840 | +7.9% | 0.02% | 0.0% |
Q1 2019 | $16,508,000 | -22.4% | 3,839,190 | +3.8% | 0.02% | -35.7% |
Q4 2018 | $21,272,000 | -54.1% | 3,699,521 | +8.2% | 0.03% | -44.0% |
Q3 2018 | $46,343,000 | +28.7% | 3,417,627 | +12.7% | 0.05% | +28.2% |
Q2 2018 | $36,005,000 | +25.0% | 3,033,261 | +18.2% | 0.04% | +14.7% |
Q1 2018 | $28,810,000 | +124.6% | 2,565,409 | +33.6% | 0.03% | +112.5% |
Q4 2017 | $12,829,000 | +13.6% | 1,920,593 | +39.2% | 0.02% | +14.3% |
Q3 2017 | $11,297,000 | +90.2% | 1,379,304 | +4.2% | 0.01% | +75.0% |
Q2 2017 | $5,941,000 | +17.1% | 1,323,308 | +43.7% | 0.01% | +14.3% |
Q1 2017 | $5,075,000 | +36.1% | 920,984 | 0.0% | 0.01% | +16.7% |
Q4 2016 | $3,730,000 | -42.6% | 920,984 | 0.0% | 0.01% | -40.0% |
Q3 2016 | $6,493,000 | +85.4% | 920,984 | +114.3% | 0.01% | +66.7% |
Q2 2016 | $3,502,000 | +0.3% | 429,700 | 0.0% | 0.01% | 0.0% |
Q1 2016 | $3,493,000 | – | 429,700 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Matrix Capital Management Company, LP | 38,974,185 | $166,030,000 | 1.81% |
Endurant Capital Management LP | 1,539,435 | $6,558,000 | 1.80% |
NEA Management Company, LLC | 17,082,611 | $72,772,000 | 0.95% |
PFM Health Sciences, LP | 3,627,900 | $15,455,000 | 0.48% |
GSA CAPITAL PARTNERS LLP | 513,388 | $2,187,000 | 0.25% |
Baker Brothers Advisors | 9,830,877 | $41,880,000 | 0.18% |
Avoro Capital Advisors LLC | 2,024,400 | $8,624,000 | 0.15% |
Vigilare Wealth Management | 54,250 | $231,000 | 0.14% |
AlphaCentric Advisors LLC | 120,000 | $511,000 | 0.14% |
Rock Springs Capital Management LP | 1,545,000 | $6,582,000 | 0.13% |